FDA con­verts Pfiz­er's Tiv­dak to full ap­proval in cer­vi­cal can­cer

Pfiz­er’s new cer­vi­cal can­cer drug Tiv­dak has been con­vert­ed from an ac­cel­er­at­ed to a full ap­proval.

The Seagen and Gen­mab-parterned drug, al­so known as ti­so­tum­ab …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER